Estrella Immunopharma, Inc. (ESLA): R&D Expense
$10.25M
Year ended 2025-12-31
$6.98M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.25M | n/a | 2026-03-18, From 2025-01-01 |
| No annual figure between 2024-06-30 and 2025-12-31. | |||
| 2024-06-30 | $4.11M | -60.7% | 2024-09-27, From 2023-07-01 |
| 2023-06-30 | $10.45M | n/a | 2024-09-27, From 2022-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | 2025-12-31 | $10.25M | n/a |
| BioCardia, Inc. (BCDA) | 2025-12-31 | $4.96M | +13.1% |
| Tevogen Inc. (TVGN) | 2025-12-31 | $11.11M | -64.2% |
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | $3.06M | -14.6% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $3.92M | -36.7% |
| Exozymes Inc. (EXOZ) | 2025-12-31 | $3.71M | +98.4% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $3.13M | +127.7% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $100.0K | -39.0% |
| Silexion Therapeutics Corp (SLXN) | 2025-12-31 | $7.14M | +22.8% |
Compare ESLA, BCDA, TVGN, ELOX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗